IAIM
NBIX icon

International Assets Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

International Assets Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Buy
113
+72
+176% +$10.7K ﹤0.01% 1631
2026
Q1 		$5.43K Sell
41
-6
-13% -$796 ﹤0.01% 1827
2025
Q4 		$6.67K Sell
47
-1,707
-97% -$247K ﹤0.01% 1759
2025
Q3 		$225K Hold
1,754
– – 0.02% 713
2025
Q2 		$220K Buy
+1,754
New +$201K 0.02% 723
2024
Q3 		– Sell
-17
Closed -$2.34K – 2364
2024
Q2 		$2.34K Buy
+17
New +$2.33K ﹤0.01% 1989
2021
Q2 		– Sell
-8
Closed -$1K – 1381
2021
Q1 		$1K Hold
8
– – ﹤0.01% 2130
2020
Q4 		$1K Buy
+8
New +$773 ﹤0.01% 2011

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

International Assets Investment Management's NBIX Position: Q2 2026 in Review

International Assets Investment Management increased its Neurocrine Biosciences (NBIX) stake by 176% in Q2 2026, buying an estimated $10.7K and bringing the position to 113 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #1631.

International Assets Investment Management first reported a position in NBIX in Q4 2020 and has held it in 8 quarters since. The position peaked at $225K in Q3 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • International Assets Investment Management held 113 shares of Neurocrine Biosciences worth $19K as of Q2 2026.
  • International Assets Investment Management bought 72 Neurocrine Biosciences shares in Q2 2026, an estimated $10.7K.
  • Neurocrine Biosciences made up ﹤0.01% of International Assets Investment Management's portfolio in Q2 2026, its #1631 holding.
  • International Assets Investment Management first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 8 quarters since.
  • International Assets Investment Management's Neurocrine Biosciences position peaked at $225K in Q3 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on International Assets Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.